vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and KADANT INC (KAI). Click either name above to swap in a different company.

KADANT INC is the larger business by last-quarter revenue ($271.6M vs $196.0M, roughly 1.4× Axsome Therapeutics, Inc.). KADANT INC runs the higher net margin — 10.2% vs -14.6%, a 24.8% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs -0.0%). KADANT INC produced more free cash flow last quarter ($44.1M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 6.7%).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

Kadant Inc. is a company that was established in 1991, as a partly privately owned subsidiary of Thermo Electron, and partly publicly traded company, and was fully spun out and renamed Kadant in 2001. The company supports papermaking, paper recycling, wood processing, material handling, and other processing industries. Kadant is a multi-national corporation with operations in Asia, Europe, North America, and South America.

AXSM vs KAI — Head-to-Head

Bigger by revenue
KAI
KAI
1.4× larger
KAI
$271.6M
$196.0M
AXSM
Growing faster (revenue YoY)
AXSM
AXSM
+65.0% gap
AXSM
65.0%
-0.0%
KAI
Higher net margin
KAI
KAI
24.8% more per $
KAI
10.2%
-14.6%
AXSM
More free cash flow
KAI
KAI
$62.8M more FCF
KAI
$44.1M
$-18.7M
AXSM
Faster 2-yr revenue CAGR
AXSM
AXSM
Annualised
AXSM
61.7%
6.7%
KAI

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
AXSM
AXSM
KAI
KAI
Revenue
$196.0M
$271.6M
Net Profit
$-28.6M
$27.7M
Gross Margin
45.2%
Operating Margin
-13.8%
15.7%
Net Margin
-14.6%
10.2%
Revenue YoY
65.0%
-0.0%
Net Profit YoY
61.9%
-12.2%
EPS (diluted)
$-0.55
$2.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
KAI
KAI
Q4 25
$196.0M
Q3 25
$171.0M
$271.6M
Q2 25
$150.0M
$255.3M
Q1 25
$121.5M
$239.2M
Q4 24
$118.8M
$258.0M
Q3 24
$104.8M
$271.6M
Q2 24
$87.2M
$274.8M
Q1 24
$75.0M
$249.0M
Net Profit
AXSM
AXSM
KAI
KAI
Q4 25
$-28.6M
Q3 25
$-47.2M
$27.7M
Q2 25
$-48.0M
$26.2M
Q1 25
$-59.4M
$24.1M
Q4 24
$-74.9M
$24.0M
Q3 24
$-64.6M
$31.6M
Q2 24
$-79.3M
$31.3M
Q1 24
$-68.4M
$24.7M
Gross Margin
AXSM
AXSM
KAI
KAI
Q4 25
Q3 25
45.2%
Q2 25
45.9%
Q1 25
46.1%
Q4 24
43.4%
Q3 24
44.7%
Q2 24
44.4%
Q1 24
44.6%
Operating Margin
AXSM
AXSM
KAI
KAI
Q4 25
-13.8%
Q3 25
-27.0%
15.7%
Q2 25
-24.5%
15.4%
Q1 25
-46.9%
14.9%
Q4 24
-61.1%
14.3%
Q3 24
-59.8%
18.0%
Q2 24
-89.5%
17.6%
Q1 24
-89.7%
14.8%
Net Margin
AXSM
AXSM
KAI
KAI
Q4 25
-14.6%
Q3 25
-27.6%
10.2%
Q2 25
-32.0%
10.2%
Q1 25
-48.9%
10.1%
Q4 24
-63.1%
9.3%
Q3 24
-61.7%
11.6%
Q2 24
-91.0%
11.4%
Q1 24
-91.1%
9.9%
EPS (diluted)
AXSM
AXSM
KAI
KAI
Q4 25
$-0.55
Q3 25
$-0.94
$2.35
Q2 25
$-0.97
$2.22
Q1 25
$-1.22
$2.04
Q4 24
$-1.54
$2.04
Q3 24
$-1.34
$2.68
Q2 24
$-1.67
$2.66
Q1 24
$-1.44
$2.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
KAI
KAI
Cash + ST InvestmentsLiquidity on hand
$322.9M
$124.5M
Total DebtLower is stronger
$254.6M
Stockholders' EquityBook value
$88.3M
$949.8M
Total Assets
$689.8M
$1.5B
Debt / EquityLower = less leverage
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
KAI
KAI
Q4 25
$322.9M
Q3 25
$325.3M
$124.5M
Q2 25
$303.0M
$95.3M
Q1 25
$300.9M
$91.7M
Q4 24
$315.4M
$94.7M
Q3 24
$327.3M
$88.4M
Q2 24
$315.7M
$73.8M
Q1 24
$331.4M
$81.4M
Total Debt
AXSM
AXSM
KAI
KAI
Q4 25
Q3 25
$254.6M
Q2 25
$245.7M
Q1 25
$273.5M
Q4 24
$285.2M
Q3 24
$323.2M
Q2 24
$342.0M
Q1 24
$306.8M
Stockholders' Equity
AXSM
AXSM
KAI
KAI
Q4 25
$88.3M
Q3 25
$73.7M
$949.8M
Q2 25
$73.1M
$926.0M
Q1 25
$53.2M
$876.0M
Q4 24
$57.0M
$847.1M
Q3 24
$92.9M
$851.7M
Q2 24
$102.9M
$807.7M
Q1 24
$144.0M
$782.7M
Total Assets
AXSM
AXSM
KAI
KAI
Q4 25
$689.8M
Q3 25
$669.3M
$1.5B
Q2 25
$639.8M
$1.5B
Q1 25
$596.7M
$1.4B
Q4 24
$568.5M
$1.4B
Q3 24
$561.5M
$1.5B
Q2 24
$548.2M
$1.5B
Q1 24
$545.7M
$1.4B
Debt / Equity
AXSM
AXSM
KAI
KAI
Q4 25
Q3 25
0.27×
Q2 25
0.27×
Q1 25
0.31×
Q4 24
0.34×
Q3 24
0.38×
Q2 24
0.42×
Q1 24
0.39×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
KAI
KAI
Operating Cash FlowLast quarter
$-18.7M
$47.3M
Free Cash FlowOCF − Capex
$-18.7M
$44.1M
FCF MarginFCF / Revenue
-9.6%
16.2%
Capex IntensityCapex / Revenue
0.0%
1.2%
Cash ConversionOCF / Net Profit
1.70×
TTM Free Cash FlowTrailing 4 quarters
$-93.9M
$145.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
KAI
KAI
Q4 25
$-18.7M
Q3 25
$1.0M
$47.3M
Q2 25
$-32.4M
$40.5M
Q1 25
$-43.4M
$22.8M
Q4 24
$-26.2M
$51.9M
Q3 24
$-18.6M
$52.5M
Q2 24
$-30.1M
$28.1M
Q1 24
$-53.5M
$22.8M
Free Cash Flow
AXSM
AXSM
KAI
KAI
Q4 25
$-18.7M
Q3 25
$988.0K
$44.1M
Q2 25
$-32.4M
$36.5M
Q1 25
$-43.7M
$19.0M
Q4 24
$-26.2M
$46.3M
Q3 24
$-18.7M
$48.3M
Q2 24
$-30.2M
$23.1M
Q1 24
$-53.6M
$16.6M
FCF Margin
AXSM
AXSM
KAI
KAI
Q4 25
-9.6%
Q3 25
0.6%
16.2%
Q2 25
-21.6%
14.3%
Q1 25
-36.0%
7.9%
Q4 24
-22.1%
17.9%
Q3 24
-17.9%
17.8%
Q2 24
-34.6%
8.4%
Q1 24
-71.4%
6.7%
Capex Intensity
AXSM
AXSM
KAI
KAI
Q4 25
0.0%
Q3 25
0.0%
1.2%
Q2 25
0.0%
1.6%
Q1 25
0.3%
1.6%
Q4 24
0.0%
2.2%
Q3 24
0.1%
1.5%
Q2 24
0.1%
1.8%
Q1 24
0.1%
2.5%
Cash Conversion
AXSM
AXSM
KAI
KAI
Q4 25
Q3 25
1.70×
Q2 25
1.55×
Q1 25
0.95×
Q4 24
2.16×
Q3 24
1.66×
Q2 24
0.90×
Q1 24
0.92×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXSM
AXSM

Segment breakdown not available.

KAI
KAI

Flow Control$94.8M35%
Capital$83.2M31%
Material Handling Systems$70.3M26%
Transferred Over Time$17.1M6%
Other$6.1M2%

Related Comparisons